Monoclonal Antibodies Specific for Murine p55 and p75 Tumor Necrosis Factor Receptors: Identification of a Novel In Vivo Role for p75

By Kathleen C. F. Sheehan, J. Keith Pinckard, Cora D. Arthur, Louis P. Dehner, David V. Goeddel,* and Robert D. Schreiber

From the Center for Immunology and Department of Pathology, Washington University School of Medicine, St. Louis, Missouri 63110; and the Department of Molecular Biology, Genentech, Inc., South San Francisco, California 94080

Summary
Monoclonal antibodies (mAbs) specific for the murine p55 and p75 tumor necrosis factor (TNF) receptors were produced after immunization of Armenian hamsters with the purified soluble extracellular domains of each receptor protein. Four p55- (55R) and five p75 (TR75)-reactive mAbs immunoprecipitated the appropriate receptor from the surface of L929 cells. None of the mAbs cross-reacted with the other TNF receptor form. The mAbs were functionally characterized by their ability to inhibit ligand binding and influence TNF-dependent L cell cytolytic activity or proliferation of the murine cytolytic T cell clone CT6. One p55-specific mAb, 55R-593, displayed agonist activity, while two other p55-specific mAbs (55R-170 and -176) were found to be TNF antagonists. The fourth mAb (55R-286) had no functional effects on cells. Several antibodies specific for the p75 TNF receptor partially inhibited recombinant murine TNF-α-dependent cytolytic activity (60%). Blocking mAbs specific for p75 but not anti-p55 inhibited TNF-mediated proliferation of CT6 T cells. When used in vivo, p55- but not p75-specific mAbs protected mice from lethal endotoxin shock and blocked development of a protective response against Listeria monocytogenes infection. In contrast, both p55 and p75 mAbs individually blocked development of skin necrosis in mice treated with murine TNF-α. These data thus demonstrate the utility of the two families of murine TNF receptor–specific mAbs and identify a novel function of the p75 TNF receptor in vivo.

TNF, originally identified by its ability to effect hemorrhagic necrosis of specific tumors (1), is now known to play a major role in promoting immunologic, inflammatory, and pathobiologic reactions (2). TNF's pleiotropic activities are induced after binding of the homotrimeric ligand to either of two distinct cell surface receptors of 55 and 75 kD that are independently expressed on a variety of different cell types (3, 4). The cDNAs and genes for the murine and human p55 and p75 TNF receptors have been cloned and expressed and the proteins they encode characterized (5-9). Although the extracellular domains of the two TNF receptors are 28% identical, no homology has been found between the intracellular domains of the two proteins (10). This observation suggests that the two receptors may be responsible for inducing distinct cellular responses. The murine p55 TNF receptor binds both murine and human TNF-α. In contrast, the murine p75 receptor binds only its homologous murine ligand and not the human homologue (8, 9).

Work is ongoing to define the functional roles of the p55 and p75 TNF receptors on various cell types. The p55 receptor is now known to be important for inducing in cells a wide variety of functions such as cytolytic activity (11, 12), antiviral activity (13), expression of manganous superoxide dismutase (14) and intercellular adhesion molecule (ICAM)1 1 (15, 16), IL-6 mRNA accumulation (17, 18), and NF-κB induction (12, 15, 19, 20). Recent experiments using p55-deficient mice have demonstrated that the p55 TNF receptor plays a physiologically important role in promoting lethal shock induced by LPS and galactosamine and in effecting antimicrobial responses to Listeria monocytogenes (21, 22). In contrast, little information is available concerning the biologic responses mediated by the p75 TNF receptor. In vitro experiments have suggested that p75 enhances p55-induced biologic responses by facilitating binding of TNF to p55 (23, 24). In addition, p75 induces proliferative responses in certain cells of hematopoietic origin and enhances expression of certain adhesion molecules such as ICAM-1 (11, 14, 25-27).

1 Abbreviations used in this paper: HuTNF, MuTNF, and MulFN, recombinant human and murine TNF-α and IFN-γ, respectively; ICAM, intercellular adhesion molecule.
Although receptor-specific mAbs have been generated against the human TNF receptors, no mAbs are currently available that are reactive with the murine TNF receptor proteins. Herein, we report the production and characterization of hamster mAbs specific for the murine p55 and p75 TNF receptors. The functional activities of these antibodies are demonstrated in well-defined in vitro systems and subsequently by use of in vivo murine models of lethal shock and anti-Listeria responses. Finally, using an in vivo model of TNF-induced skin necrosis in mice, we identify a novel physiologic role of p75.

Materials and Methods

**Animals.** C57Bl/6J, CBA/J, BALB/cByJ, and C3H/HeJ female mice 6-12 wk of age were purchased from The Jackson Laboratory (Bar Harbor, ME) and maintained in microisolator cages. Male Armenian hamsters were obtained from Cytogen Research and Development, Inc. (Cambridge, MA). Goats were purchased through and maintained at the Washington University School of Medicine Tyson Research Center.

**Reagents and Materials.** Media, supplements, and buffers used in these experiments were purchased or prepared as previously described (28, 29) and contained <0.005 endotoxin units/ml as determined by the Limulus amebocyte lysate assay (BioWhittaker Inc., Walkersville, MD). Purified recombinant murine TNF-α (MuTNF) (1.2 x 10^8 U/mg), recombinant human TNF-α (HuTNF) (5.6 x 10^6 U/mg) and recombinant murine IFN-γ (MuIFN) (4.7 x 10^6 U/mg) were produced by Genentech, Inc. (San Francisco, CA). MuIFN was radiolabeled to a specific activity of 10.8 μCi/μg by use of Na^125I (ICN Biomedicals, Inc., Irvine, CA) and Iodo-beads (Pierce Chemical Co., Rockford, IL) according to the manufacturers’ directions. Iodinated HuTNF (800 Ci/mmol) was purchased from Amersham (Arlington Heights, IL). Purified soluble extracellular domains of the p55 and p75 murine TNF receptors were prepared as described (8, 30) and radioiodinated by use of the Bolton-Hunter reagent (ICN Biomedicals, Inc.) according to the manufacturer’s directions to a specific activity of 3.2 and 9.2 μCi/μg, respectively. LPS (Escherichia coli strain 0111:B4) and β-galactosamine were obtained from Sigma Chemical Co. (St. Louis, MO).

**Antibodies.** The following previously described and characterized hamster mAbs were used in this study: TN3-19.12 (anti-murine TNF-α) (29), JAMA-147 (anti-murine type I IL-1 receptor) (31), and H22 (anti-murine IFN-γ) (28); L2-3D9 (29) and 6C8 (32) are control hamster mAbs not reactive with naturally occurring murine proteins. Polyvalent rabbit p55- and p75-specific antisera were produced as previously described (11). Anti-hamster IgG was produced by immunization of goats with purified Armenian hamster IgG. Hamster IgG–specific antibodies were purified from immune sera by affinity chromatography by use of agarose-bound Armenian hamster IgG. Purified antibodies were biotinylated by use of the Enzotin reagent (Enzo Biochemical, Inc., New York) according to the manufacturer’s instructions.

**Production of Anti-TNF Receptor Antibodies.** Hamster mAbs were generated from Armenian hamsters as previously described (28, 29). Animals were immunized intraperitoneally with the soluble purified extracellular domains of either the p55 or p75 murine TNF receptor (10 μg) emulsified in CFA and boosted three times with the same quantity of antigen in IFA at 2-wk intervals. 3 wk after the last boost, each animal was given an i.v. injection of 10 μg of the appropriate antigen diluted in sterile saline. Cultures were screened by immunoprecipitation of radiolabeled soluble receptor protein (2 ng/well) as previously described (33).

For the anti-p55 fusion, 565/612 growth-positive wells were obtained, which yielded 20 separate cultures producing p55-specific antibody (3.54%). The p75 fusion produced 236/408 growth-positive wells, and 12 produced p75-specific antibodies (5.08%). Antibody-producing hybridomas were cloned by limiting dilution. mAbs were purified from close culture supernatants by use of Affi-Prep Protein A Silica (Bio-Rad Laboratories, Richmond, CA) chromatography as previously described (29) and HPLC gel filtration. All antibody stocks contained <200 pg endotoxin per milligram of protein when analyzed by the Limulus amebocyte lysate assay.

**Ligand Binding Inhibition.** The ability of anti-p55 and anti-p75 mAbs to block ligand binding to L929 was determined by use of a protocol similar to that described previously (34). 4 million L929 cells were preincubated for 1 h at 4°C with serial dilutions of mAb and then incubated with radiolabeled recombinant TNF in a final total volume of 200 μl. To monitor binding of TNF to p55, 4 ng ^125I-labeled human TNF was used in the experiment since human TNF binds only to murine p55 TNF receptors (8). To monitor binding of TNF to p75 TNF receptors, cells were first incubated with 5 μg unlabeled human TNF for 1 h at 4°C to block the p55 TNF receptor, exposed to mAb, and then incubated with 20 ng ^125I-labeled murine TNF. The level of nonspecific binding in each experiment was determined by adding a 100-fold excess of unla-beled human or murine TNF to control wells. Cell-associated and free radioactivity were separated by centrifugation over a pthalate oil mixture (34) and the percent inhibition of specific binding determined.

**Immunoprecipitation, SDS-PAGE, and Immunoblotting.** L929 cells (2 x 10^6) were lysed in 1 ml PBS containing 1% Triton X-100 and protease inhibitors as previously described (35). Samples were precleared by 1-h incubation with 50 μl protein A-Sepharose slurry (Pharmacia Fine Chemicals, Piscataway, NJ) and then incubated overnight at 4°C with 20 μg mAb. 50 μl of protein A-Sepharose was added to each sample and incubated an additional 4 h. Beads were pelleted by centrifugation and washed three times with 1 ml immunomix (35) and once with 1 ml PBS. Beads were resuspended in 70 μl of Laemmli sample buffer (36), boiled 10 min, and centrifuged.

Half of each sample was applied to a 12% polyacrylamide gel and subjected to SDS-PAGE according to the method of Laemmli by use of a mini-Protein II gel apparatus (Bio-Rad Laboratories) (36). Western blot analysis was performed as previously described (35). Filters were washed in PBS containing 0.05% Tween-20 and incubated 2 h with biotin-conjugated anti-p55 (5SR-593) or anti-p75 (TR75-54) at 2 μg/ml. After washing, filters were incubated 15 min with peroxidase-conjugated streptavidin (1:4,000). washed, and developed by use of the enhanced chemiluminescence system (ECL; Amersham).

**L929 Cytolytic Assay.** TNF-dependent L929 killing activity was quantitated as previously described (29). Briefly, L929 cell cultures (80% confluent) were harvested in EDTA, washed, resuspended to 7.5 x 10^5 cells/ml in medium, and treated with actinomycin D (2 μg/ml final concentration). After 2 h at 37°C, 100 μl of the cell suspension was mixed with 100 μl of serial dilutions of either mAb or TNF in 96-well flat-bottom culture plates. In assays in which cell-bound mAb was cross-linked, 20 μg of affinity-purified goat anti-hamster Ig was added per well. After 18 h of culture at 37°C, viability of the cell cultures was determined by vital dye staining with crystal violet as previously described (29).

**Neutralization of TNF Activity.** Neutralization of TNF-dependent cytolytic activity by mAb was quantitated by use of a modi-
fication of the TNF bioassay described above. Different concentrations of mAb were preincubated with actinomycin D-treated L929 cells (7.5 x 10^4/well) for 2 h at 37°C. A constant amount of TNF was then added to each well and the cultures incubated an additional 18 h at 37°C. Cell viability was assessed by crystal violet staining.

Nitric Oxide Assay. Nitric oxide induction in murine L929 fibroblasts by MuIFN and TNF was assayed essentially as described previously (37, 38).

CT6 Proliferation. TNF-dependent proliferation of the murine CT6 cytotoxic T-cell line was assayed as previously described (11). For inhibition studies, cells were preincubated with mAb for 2 h at 37°C before addition of 2 ng/well MuTNF. Cultures were pulsed with [3H]thymidine (0.5 μCi/well) during the final 4–6 h of a 24-h culture period and cpm incorporated into DNA determined.

LPS-Galactosamine-induced Shock. Groups of 10 C57Bl/6J mice were injected intraperitoneally with either pyrogen-free saline or mAb (250 μg) 24 h before treatment with a combination of 600 ng LPS and 10 mg D-galactosamine (intraperitoneally in 0.5 ml). Survival was monitored at 4- to 6-h intervals over a period of 72 h (39).

Listeria Infection. Mice were pretreated with either saline or mAb injected intraperitoneally 6 h before i.p. administration of 3,000 CFU of Listeria monocytogenes as described (40). Survival was monitored twice daily over a 2-wk period.

TNF-mediated Skin Necrosis. Mice were pretreated with either pyrogen-free saline or mAb injected intraperitoneally for a period of 72 h. The animals were injected subcutaneously with either saline, MuTNF (250 μg) or a mixture of 3 μg TNF and mAb (50 μg) in 0.2 ml. Injections were continued on a daily basis. Mice were observed twice daily for the appearance of local skin hemorrhage and necrosis. At various times after treatment, the mice were bled, killed, and tissue prepared for histology according to standard procedures.

Results

Immunoprecipitation of Receptor from Cell Surfaces. Purified mAbs were examined for their ability to specifically precipitate intact receptor from cell surfaces. Western blot analysis showed that three of the anti-p55 mAbs (55R-593, -176, and -170) precipitated a protein of the appropriate molecular mass from L929 cell lysates (Fig. 1, top). In a separate experiment, similar results were obtained with a fourth p55-specific mAb, 55R-286 (not shown). No p55 was precipitated by any of the anti-p75 mAbs (TR75-32, TR75-45, or TR75-54) or control hamster IgG (55R-286, not shown). Binding of p55 was inhibited by any of the anti-p75 mAbs (TR75-32, TR75-45, or TR75-54) or control hamster IgG specific for the murine type I IL-1 receptor (JAMA-147 or TNFα (TN3-19.12). Conversely, the p75 receptor was precipitated only by mAb generated against the murine p75 TNF receptor extracellular domain (Fig. 1, bottom). Western blot analysis revealed that the anti-p75 mAb precipitated two components, a major component of 70 kD and a minor component of 60 kD. Similar patterns were seen with two additional p75-specific mAbs, TR75-4 and TR75-89 (data not shown). No TR75-reactive bands were identified after precipitation with either the anti-p55 mAb or control IgG. The antigenic specificity of each mAb was verified by ELISA that used immobilized purified p55 or p75 extracellular domain (data not shown). These results thus established that each family of mAb reacted only with the class of TNF receptor used for immunization and that the antibodies recognized the natural receptor molecules derived from whole cells.

Inhibition of Ligand Binding. Radioligand-binding studies were performed on murine L929 cells, which express both p55 and p75 TNF receptors to further characterize the specificity of each mAb. To monitor effects on the p55 TNF receptor, the antibodies were tested for their ability to inhibit binding of radiolabeled HuTNF to murine L929 cells since the human ligand binds exclusively to the murine p55 TNF receptor. Incubation of L929 with 55R-593, 55R-176, or 55R-170 produced a dose-dependent inhibition of binding of 4 ng [125I]HuTNF (Fig. 2A). 50% inhibition of HuTNF binding was achieved at mAb doses of 4, 5, and 1,500 ng, respectively. No inhibition was detected with 55R-286, even at mAb doses >75 μg/well. Binding of HuTNF was not inhibited with the 6C8 control hamster IgG (Fig. 2A) or p75-specific mAb (data not shown).
blocking and nonblocking mAbs. Inhibition was observed with the TR75-4 and TR75-89 mAbs.

To inhibit ligand binding, L929 cells were pretreated with saturating concentrations (5 μg) of unlabeled HuTNF (to block all of the p55 receptors), followed by addition of 4 ng radiiodinated HuTNF. Cell-associated and free radioactivity were separated by centrifugation through oil. Maximum binding of 125I-HuTNF was 15,000 cpm, while nonspecific binding in the presence of 5 μg unlabeled HuTNF was <2%.

To assess p75-specific ligand binding, L929 cells were first incubated with saturating concentrations of HuTNF (5 μg) for 1 h at 4°C before addition of various doses of TR75-45, -32, -45, -54, and -89 or control hamster Ig 6C8. After 1 h at 4°C, 20 ng radiiodinated MuTNF was added for an additional hour. Samples were harvested as above and the percent binding inhibition determined. Binding of 20 ng labeled MuTNF yielded 5,000 cpm, and nonspecific binding in the presence of an additional 5 μg unlabeled MuTNF was 1.89%.

Figure 2. Inhibition of ligand binding by p55- or p75-specific TNF receptor mAbs. (A) L929 cells (4 × 10^6/well) were incubated with increasing concentrations of 55R-593, -286, -176, -170, or control hamster Ig 6C8 for 1 h at 4°C before addition of 4 ng radiiodinated HuTNF. Cell-associated and free radioactivity were separated by centrifugation through oil. Maximum binding of 125I-HuTNF was 15,000 cpm, while nonspecific binding in the presence of 5 μg unlabeled HuTNF was <2%. (B) To assess p75-specific ligand binding, L929 cells were first incubated with saturating concentrations of HuTNF (5 μg) for 1 h at 4°C before addition of various doses of TR75-4, -32, -45, -54, and -89 or control hamster Ig 6C8. After 1 h at 4°C, 20 ng radiiodinated MuTNF was added for an additional hour. Samples were harvested as above and the percent binding inhibition determined. Binding of 20 ng labeled MuTNF yielded 5,000 cpm, and nonspecific binding in the presence of an additional 5 μg unlabeled MuTNF was 1.89%.

To determine the agonist activity of the TNF receptor-specific mAb in the in vitro L929 killing assay in the absence of exogenous TNF. Only 55R-593 induced L929 cell lysis in a dose-dependent fashion (Fig. 3 A). However, addition of goat anti-hamster Ig to cultures pretreated with 55R-170 and -176 induced L929 lysis, while cross-linking of 55R-286-treated cultures or cultures treated with the 6C8 control mAb failed to induce cell killing (data not shown). The efficacy of 55R-593–induced L929 killing was not affected by antibody cross-linking. None of the anti-p75 mAbs induced cytolysis activity when used alone (Fig. 3 B), in combination, or when cross-linked with anti-hamster Ig (data not shown). These results thus demonstrate that 55R-593 displays TNF agonist activity and confirms that L929 cell-killing activity can be effected solely through p55 receptor engagement, but not p75 engagement.

The antibodies were also tested for their capacity to inhibit TNF-dependent L929 killing. The p55-specific mAbs 55R-170 and -176 blocked the lytic activity of 30 pg MuTNF in a dose-dependent fashion. 50% inhibition of TNF activity was obtained with 1,000 and 20 ng of the mAbs, respectively (Fig. 3 C), and corresponds to their relative abilities to inhibit ligand–receptor interaction. The p55 agonist mAb 55R-593, the nonblocking p55 mAb 55R-286, and control mAb failed to inhibit MuTNF-dependent cytolysic activity. When the experiments were conducted with HuTNF (which binds only to the murine p55 TNF receptor), similar results were obtained, except that 55R-170 and -176 were more efficient inhibitors (ID_{50} = 35 and 2 ng, respectively) (Fig. 3 E). Thus, mAbs 55R-170 and -176 act as TNF antagonists in the L929 killing assay. When similar experiments were performed with anti-p75 mAbs, partial inhibition of MuTNF lytic activity (up to ~60%) was noted (Fig. 3 D). However, the anti-p75 mAbs, even at doses of 30 μg/well, failed to inhibit L cell killing mediated by HuTNF (Fig. 3 F). An identical pattern of results was obtained when these two mAb families were tested for their ability to induce or inhibit TNF-mediated nitric oxide production (data not shown).

To examine whether the anti-p75 mAbs affected biologic responses mediated solely by the p75 TNF receptor, we used an assay that monitors murine TNF–induced proliferation of the murine CT6 cytotoxic T cell line. This cell line proliferates in response to polyvalent p75-specific antisera, but not p55-specific antisera (11). While none of the p75-specific mAbs elicited a proliferative response alone, all of the p75-specific mAbs induced significant CT6 expansion when cross-linked with goat anti-hamster Ig (data not shown). None of the p55-specific mAbs, either alone or after cross-linking, induced proliferation of CT6. These data thus confirm that clustering of the p75 TNF receptor is sufficient to induce a proliferative response in these cells. In contrast, TR75-45, -54, and -32 inhibited CT6 proliferative responses induced by 2 ng MuTNF in a dose-dependent manner (Fig. 4 B). The ID_{50} values for each mAb (2, 5, and 22 ng, respectively) correlated with the ability of each mAb to block ligand–receptor interaction. TR75-4 and -89 did not display functional inhibitory activity. Antibodies reactive with p55 TNF receptor had no significant inhibitory effect on TNF-dependent CT6 proliferation (Fig. 4 A).
**Effects of p55 and p75 mAb In Vivo**

Pharmacokinetic studies performed on each antibody in naive BALB/c mice established that all mAbs displayed serum half-lives of ~2 d (data not shown). The half-life of each antibody remained unchanged in mice that received four mAb injections over a 16-wk period. Thus the hamster anti-TNF receptor mAbs were not immunogenic in mice.

To examine the efficacy of the receptor-specific mAbs in vivo, we initially used two experimental systems (LPS/galactosamine-mediated lethal shock and resistance to infection by *L. monocytogenes*), which, based on experiments with p55-deficient mice, are known to be obligatorily dependent on p55 TNF receptor engagement (21, 22). Animals pretreated with either saline or control hamster IgG succumbed to the lethal combination of LPS and galactosamine within 24 h (Fig. 5 A). Pretreatment of mice with 250 μg TN3-19.12 (a neutralizing hamster mAb specific for murine TNF-α) completely protected mice from lethal shock. Mice pretreated with the antagonistic 55R-170 mAb were also protected from lethal shock. Similar results were obtained by use of the other p55 antagonist mAb 55R-176 (data not shown). In separate dose-response experiments, 40 μg of 55R-170 was sufficient to provide complete protection (data not shown). In contrast, the antagonistic anti-p75 TNF receptor mAb TR75-54 was not protective at any dose.

In the *Listeria* infection model, mice treated either with

---

**Figure 3.** Agonist/antagonist activity of TNF receptor mAbs for L929 killing. Various dilutions of anti-p55 (A, C, and E), anti-p75 (B, D, and F) or control Ig 6C8 were preincubated with actinomycin D-treated L929 cells for 2 h at 37°C before addition of either medium (A and B) or 30 pg/well MuTNF (C and E) or 700 pg/well HuTNF (D and F). Monolayer viability was assessed after 18 h by vital dye uptake. Untreated control monolayers exhibited an absorbance at 540 nm of 1.2 (A and B) or 1.5 (C–F). Incubation with murine or human TNF resulted in readings of 0.32 and 0.22, respectively.
Figure 4. Anti-p75 inhibition of TNF-mediated CT6 proliferation. CT6 cells (5 x 10^4) were incubated with anti-p55 (A), anti-p75 (B), or control hamster mAb 6C8 for 2 h at 37°C before addition of 2 ng MuTNF. Cultures were pulsed after 20 h with [3H]thymidine for an additional 4-6 h and the percent of control response determined. Cultures stimulated with 2 ng MuTNF alone yielded 12,300 cpm with background counts <3,500.

Figure 5. In vivo activity of TNF receptor–specific mAbs. (A) LPS/galactosamine–mediated lethal shock. Groups of 10 C57Bl/6 mice were treated with saline or 250 µg mAb 24 h before challenge with a combination of LPS (600 ng) and D-galactosamine (10 mg). Survival was monitored over a 48-h period. (B) Listeria infection. Groups of 5 C3H/HeJ mice were injected intraperitoneally with 250 µg antibody 6 h before infection with 3,000 live Listeria organisms. Survival was monitored twice daily over a 10-d period. Depicted is one of six representative experiments.

saline or irrelevant hamster mAb mounted a protective anti-Listeria response and survived infection with 3,000 live Listeria organisms (Fig. 5 B). Mice treated with anti-TNF became susceptible to lethal infection and died. Animals treated with the antagonist p55-specific mAb (55R-170) failed to generate an anti-Listeria response and succumbed to the infection. As little as 25 µg of 55R-170 was sufficient to render all the animals susceptible to infection (data not shown). In contrast, TR75-54 did not inhibit the development of an anti-Listeria response in mice. Subsequent testing of TR75-32, -45, and -54 at doses of 250 and 500 µg per mouse showed that none of the p75-specific mAbs affected development of anti-Listeria responses (not shown). Thus, in both in vivo models, anti-p55–treated mice responded similarly to mice lacking the p55 TNF receptor. Moreover, antibody blockade of p75 was without functional consequences.

p75 TNF Receptor Engagement Is Required for MuTNF–mediated Skin Necrosis. Whereas the aforementioned studies confirmed the physiologic requirement of p55 TNF receptors in promoting protective and immunopathologic responses to bacteria and their products in vivo, no information was obtained that helped define the physiologic role of p75 TNF receptors. Insights into p75’s biologic role in vivo were gained from experiments being conducted to explore TNF’s immunosuppressive activities. In these studies, daily subcutaneous injections of either murine or human TNF into mice led to a state of immunosuppression that blocked xenograft rejection (41) and inhibited T cell priming to the soluble protein antigen, hen egg lysozyme (Sheehan, K., and R. Schreiber, unpublished observations). During the course of these experiments, we observed that subcutaneous injection of 3 µg MuTNF produced severe hemorrhage in the skin and subsequent necrosis at the injection site (Fig. 6 B), while s.c. injection of 3 or 30 µg HuTNF did not (Fig. 6 C). In CBA/J mice, the lesion induced with MuTNF was observed after three to five daily injections. The lesion initially presented as a reddening of the skin, followed by intradermal hemorrhage and skin necrosis. Histologically, the full-thickness skin and subcutaneous sections of the saline- and HuTNF-treated mice disclosed an absence of microscopic abnormalities (Fig. 7, A and C) to correspond with the unremarkable gross features depicted in Fig. 6, A and C. In contrast, early epidermal necrosis, transdermal neutrophilia and hemorrhage, subcutaneous hemorrhage, and recent thrombi were present in the MuTNF-treated mice (Fig. 7 B, inset). This result thus suggested that the p75 TNF receptor was involved in this process.
Figure 6. Prevention of MuTNF-induced skin necrosis by anti-p55 and anti-p75 TNF receptor–specific mAbs. Mice were pretreated on day -1 with either saline or 100 μg of antibody intraperitoneally and injected daily with 3 μg TNF alone or combined with 50 μg mAb subcutaneously over a period of 7 d. (A) Saline alone; (B) MuTNF only; (C) HuTNF only; (D) MuTNF + 6C8 control IgG; (E) MuTNF + 55R-170; and (F) MuTNF + 75-54.

To further confirm the roles of the p55 and p75 TNF receptors in this process, mice were treated with MuTNF either alone or in combination with control or antagonistic p55- or p75-specific mAbs. None of the mAbs individually or collectively induced the skin necrosis reaction (data not shown). Pretreatment of mice with antagonistic p75 mAbs (TR75-32 or -54) completely blocked the development of the skin reaction (Fig. 6 F) as well as any histologic changes (Fig. 7 F). Similar results were obtained by use of the p55-specific antagonistic mAb 55R-170 (Figs. 6 E and 7 E). Control hamster Ig was without effect, resulting in a composite of microscopic changes virtually identical to those in mice treated with MuTNF alone (Fig. 7 B) with epidermal necrosis, hemorrhage, neutrophilia, and thrombosis (Figs. 6 D and 7 D). These results thus demonstrate, for the first time, an in vivo role for the p75 TNF receptor and suggest that p75 engagement may be directly involved in certain types of acute inflammatory and hemorrhagic reactions.

Discussion

The studies presented here document the production of hamster mAbs specific for the extracellular domains of the p55 and p75 murine TNF receptors. These reagents represent the first murine TNF receptor–specific mAbs to be generated. Each member of the anti-p55 or anti-p75 mAb family displayed strict specificity for the receptor form used for immunization. Within the anti-p55 family, 55R-286 did not interfere with p55-TNF interaction, while 55R-170, -176, and -593 blocked the ability of p55 to bind ligand in a dose-dependent manner. Three p75-specific mAbs (TR75-32, -45, and -54) were identified that blocked ligand–receptor interaction, while two others (TR75-4 and -89) did not.

Functionally, the antibodies could be distinguished by their effects in well-defined in vitro TNF bioassays. By use of the L cell–killing assay, the anti-p55 mAb family was found to contain one mAb (55R-593) that acted as a TNF agonist, two (55R-170 and -176) that acted as antagonists, and one (55R-286) that did not affect TNF’s actions on p55. The production of an agonistic anti-murine p55 TNF receptor mAb is notable because its functional activity makes it unique among anti-p55 mAbs. Although it has been shown that signaling through the p55 TNF receptor is initiated by oligomerization of surface receptors using either polyvalent anti-p55 sera (11, 42) or homotrimeric ligand (43), the activity of the 55R-593 mAb presented in this report suggests that dimerization of the p55 TNF receptor may be sufficient to
Figure 7. Histologic examination of TNF-mediated skin necrosis. Mice were treated as above with 100 μg antibody intraperitoneally on day -1 and 3 μg TNF alone or in combination with 50 μg antibody subcutaneously daily. After 4 d, mice were killed and tissue processed and stained with hematoxalin and eosin. In vivo treatments are as follows: (A) saline only; (B) MuTNF alone; (C) HuTNF alone; (D) MuTNF + 6C8 control IgG; (E) MuTNF + 55R-170; and (F) MuTNF + TR75-32. ×200.
induce a biologic response in these cells. Importantly, the
agonistic p55-specific mAb could be converted into agonists
after cross-linking. In fact, in early experiments, small amounts
of high molecular weight mAb aggregates present in the
purified antibody preparations led to an agonist action of 55R-
170 and -176. Addition of a gel filtration step to the mAb
purification procedure separated the high molecular mass ag-
gregates that displayed potent agonist activity from the bulk
of the monomeric mAbs that displayed antagonistic activity.
When 55R-593 was subjected to the same gel filtration pro-
cedure, the agonist activity coeluted with monomeric anti-
body, con- firming that 55R-593 acted as an agonist in its
native form. Thus, these results not only document the func-
tional activity of the p55-specific mAbs, but also confirm the
concept that engagement of p55 is both necessary and suffi-
cient to induce killing of L929 cells.

The same assays were used to show that the anti-p75 mAb
family contained three members that acted as p75 antago-
nists (TR75-32, -45, and -54) and two that were unable by
themselves to affect TNF-dependent biologic responses in cells
(TR75-4 and -89). By use of the CT6 proliferation assay,
TR75-32, -45, and -54 were found to inhibit MuTNF-driven
proliferative responses in a dose-dependent manner, while
TR75-4 and -89 did not. These mAbs represent the only
reagents currently available that display antagonist activity
for the murine p75 TNF receptor and thus document that
engagement of p75 is both necessary and sufficient to induce
proliferative responses in CT6 cells.

The p75 antagonist mAbs also partially inhibited MuTNF-
dependent L cell killing. Inhibition was never complete
(40–60%) and could be overcome if higher concentrations of
murine TNF were used. Moreover, none of the anti-p75 re-
agents effected L cell killing when cross-linked in the ab-

cence of TNF. These results thus support the model where
p75 plays an accessory role in the killing process. The precise
role of p75 in mediating L cell killing remains controversial.
Heller et al. (23, 24) proposed that p75 can directly signal
for cytoxicity, while Tartaglia et al. (12, 30) proposed that
p75 facilitates ligand uptake onto p55 and that p55 is the
sole TNF receptor responsible for initiating the L cell-killing
response. Recently, the latter "ligand-passing model" has been
supported by the results of structural analyses of the two TNF
receptors' intracellular domains. The p55 intracellular domain
contains a "death domain" similar to that found in the intra-
cellular domain of the Fas antigen that is important in effecting
cell killing (44), while the p75 TNF receptor does not. More-
over, additional support for a ligand-passing function has been
derived from the characterization of mice with selec-
tive genetic deficiencies of either the p55 (21, 22) or p75 (44a)
TNF receptors.

To initially examine the potential usefulness of the anti-
p55 and -p75 mAbs in vivo, we used two well-characterized
murine models (39, 45) that are known to be unequivocally
dependent on endogenous TNF production. As little as 25
or 40 μg of antagonistic anti-p55 inhibited development of a
protective immune response to L. monocytogenes in naive
mice and protected normal mice from the lethal effects of
LPS/galactosamine, respectively. In contrast, up to 500 μg
quantities of antagonistic p75 TNF receptor–specific mAbs
were without biologic effects. Importantly, these results recapitulate the observations made by others using mice lacking
p55 (21, 22) or p75 (44a) and thereby validate the in vivo
effects of our anti-p55 and anti-p75 mAbs.

The characterization of the specificities and functional ac-
tivities of the murine TNF receptor–specific mAbs was based
on the known structure and function of the two receptors.
Whereas definitive experiments have now been performed
that define at least some of the physiologic roles of the p55
TNF receptor as they occur in vivo, little information is avail-
able concerning the physiologic function of the p75 TNF
receptor. The availability of antagonistic mAbs specific for
the murine p75 TNF receptor has permitted us to identify a
heritofore unrecognized role of this protein in promoting
inflammatory responses. Previous studies by others (46) have
indicated that TNF plays an important role in the develop-
ment of naturally occurring cutaneous diseases. Moreover,
subcutaneous injection of highly purified recombinant TNF
into the skin of normal mice and rabbits has been shown by
some groups to induce intradermal hemorrhage and skin
necrosis (47, 48). In studies in which human TNF was ad-
ministered to experimental animals, the development of the
cutaneous inflammatory response was found to require the
additional presence of bacterial products (49), whereas repeti-
tive subcutaneous administration of LPS-free murine TNF
to mice led to generation of clear necrotic skin lesions (46, 48).

Based on the recognized differential species specificity dis-
played by the p55 and p75 murine TNF receptors for human
versus murine TNF, the previous discrepant results suggested
that both p55 and p75 TNF receptors might be involved in
the process. In this report, we show that whereas repeated
injections of MuTNF induced frank intradermal hemorrhage
and severe skin necrosis, repeated injections of up to 10 times
larger quantities of human TNF were without effect. This
result suggested that p75 was involved in the inflammatory
skin reaction. This hypothesis was supported by our obser-
vation that TNF-induced skin necrosis could be inhibited by
administration of antagonistic p75-specific mAbs. Moreover,
since skin necrosis was also inhibited by blocking p55-specific
mAbs, the ultimate development of in vivo inflammatory re-
sponses in the skin must be due to engagement of both TNF
receptor forms.

At this time, the identity of the cells whose function is
regulated by the p75 and p55 TNF receptors remains un-
known. It is also unclear whether the dual requirement for
p55 and p75 in this process involves a single cell population
that is stimulated by engagement of both types of TNF
receptors or multiple cell populations that are specifically in-
duced to perform their function through engagement of one
or the other TNF receptors. The gross and histologic find-
ings in this study, in particular the presence of neutrophilia, in-
tense hemorrhage, and thrombosis, would suggest that
endothelial cells and neutrophils may be important cellular par-

ticipants in this model. It is noteworthy that, based on in
vitro experiments, others (50) have suggested that p75 may
be important in effecting biologic response induction in en-
dothelial cells. Studies are currently underway in the labora-

615 Sheehan et al.
tory to define the precise physiologic roles of p55 and p75 in promoting inflammatory reactions.

Thus, we have documented the production and antigen-binding characteristics of two novel families of hamster mAbs specific for the murine p55 and p75 TNF receptors. The ability of these mAbs to function in vitro and in vivo coupled with their lack of immunogenicity in vivo provides the opportunity to modulate TNF-mediated responses in a receptor-specific fashion. The availability of these monoclonal murine TNF receptor–specific reagents will thus facilitate investigations aimed at defining the molecular basis for TNF’s pleiotropic actions and the physiologic roles of the two TNF receptors in vivo.

The authors thank Richard Weber (Genentech Inc.) for the production, purification, and characterization of the soluble extracellular domains of the p55 and p75 murine TNF receptors.

This research was supported by grants AI-24854, CA-43059, and DK-20579 from the National Institutes of Health, and grants from the U.S. Army and Genentech, Inc.

Address correspondence to Robert D. Schreiber, Department of Pathology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110. D. V. Goeddel’s present address is Tularik, Inc., 270 East Grand Avenue, South San Francisco, CA 94080.

Received for publication 19 July 1994 and in revised form 4 October 1994.

Note Added in Proof: While this paper was in press, the paper describing the generation and characterization of p75 TNF receptor deficient mice, referred to in the Discussion, by Erickson et al. (44a), was accepted and published.

References

1. Carswell, E.A., L.J. Old, R.L. Kassel, S. Green, N. Fiore, and B. Williamson. 1975. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA. 72:3666–3670.
2. Old, L.J. 1990. Tumor necrosis factor. In Tumor Necrosis Factor: Structure, Mechanism of Action, Role in Disease and Therapy. B. Bonavida and G. Granger, editors. S. Karger, Basel. 1–30.
3. Kull, F.C., Jr., S. Jacobs, and P. Cuatrecasas. 1985. Cellular receptor for 125I-labeled tumor necrosis factor: specific binding, affinity-labeling, and relationship to sensitivity. Proc. Natl. Acad. Sci. USA. 82:5756–5760.
4. Ryffel, B., and M.J. Mihatsch. 1993. TNF receptor distribution in human tissues. Int. Rev. Exp. Pathol. 34:149–155.
5. Loetscher, H., Y.-C.E. Pan, H.-W. Lahn, R. Gentz, M. Brockhaus, H. Tabuchi, and W. Lesslauer. 1990. Molecular cloning and expression of the human 55 kDa tumor necrosis factor receptor. Cell. 61:351–359.
6. Schall, T.J., M. Lewis, K.J. Koller, A. Lee, G.C. Rice, G.H.W. Wong, T. Gatanaga, G.A. Granger, R. Lentz, H. Raab, et al. 1990. Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell. 61:361–370.
7. Smith, C.A., T. Davis, D. Anderson, L. Solam, M.P. Beckmann, R. Jerzy, S.K. Dower, D. Cosman, and R.G. Goodwin. 1990. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science (Wash. DC). 248:1019–1023.
8. Lewis, M., L.A. Tartaglia, A. Lee, G.L. Bennett, G.C. Rice, G.H.W. Wong, E.Y. Chen, and D.V. Goeddel. 1991. Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc. Natl. Acad. Sci. USA. 88:2830–2834.
9. Goodwin, R.G., D. Anderson, R. Jerzy, T. Davis, C.I. Brannan, N.G. Copeland, N.A. Jenkins, and C.A. Smith. 1991. Molecular cloning and expression of the type I and type II murine receptors for tumor necrosis factor. Mol. Cell. Biol. 11:3020–3026.
10. Dembic, Z., H. Loetscher, U. Gubler, Y.E. Pan, H. Lahn, R. Gentz, M. Brockhaus, and W. Lesslauer. 1990. Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences. Cytokine. 2:231–237.
11. Tartaglia, L.A., R.F. Weber, I.S. Figari, C. Reynolds, M.A. Palladino, Jr., and D.V. Goeddel. 1991. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc. Natl. Acad. Sci. USA. 88:9292–9296.
12. Tartaglia, L.A., M. Rothe, Y.-F. Hu, and D.V. Goeddel. 1993. Tumor necrosis factor’s cytotoxic activity is signaled by the p55 TNF receptor. Cell. 73:213–216.
13. Wong, G.W.H., L.A. Tartaglia, M.S. Lee, and D.V. Goeddel. 1992. Antiviral activity of tumor necrosis factor (TNF) is signaled through the 55-kDa receptor, type I TNF. J. Immunol. 149:3350–3353.
14. Tartaglia, L.A., and D.V. Goeddel. 1992. Two TNF receptors. Immunol. Today. 13:151–153.
15. Mackay, F., H. Loetscher, D. Stueber, G. Gehr, and W. Lesslauer. 1993. Tumor necrosis factor α (TNF-α)–induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55. J. Exp. Med. 177:1277–1286.
16. Trefzer, U., M. Brockhaus, H. Loetscher, F. Parlow, A. Kapp, E. Schöpf, and J. Kruttmann. 1991. 55-kd tumor necrosis factor receptor is expressed by human keratinocytes and plays a pivotal role in regulation of human keratinocyte ICAM-1 expression. J. Invest. Dermatol. 97:911–916.
17. Libert, C., S.V. Bladel, P. Brocquaert, and W. Fiers. 1991. The influence of modulating substances on tumor necrosis factor and interleukin-6 levels after injection of murine tumor necrosis factor or lipopolysaccharide in mice. J. Immunother. 10:227–235.
18. Brakebusch, C., Y. Nophar, O. Kemper, H. Engelmann, and D. Wallach. 1992. Cytoplasmic truncation of the 55 tumour necrosis factor (TNF) receptor abolishes signaling, but not induced shedding of the receptor. EMBO (Eur. Mol. Biol. Organ.) 11:943–950.
19. Kruppa, G., B. Thoma, T. Machleidt, K. Wiegmnn, and M. Krönke. 1992. Inhibition of tumor necrosis factor (TNF)-mediated NF-kappa B activation by selective blockade of the
human 55-kDa TNF receptor. *J. Immunol.* 148:3152–3157.
20. Hohmann, H.-P., R. Remy, B. Boschl, and A.P.G.M. Van Loon. 1990. Tumor necrosis factors-α and -β bind to same two types of tumor necrosis factor receptors and maximally activate the transcription factor NF-κB at low receptor occupancy and within minutes after receptor binding. *J. Biol. Chem.* 265:15183–15188.
21. Pfeffer, K., T. Matsuyama, T.M. Kundig, A. Wakeham, K. Kishihara, A. Shahinian, K. Wiegmann, P.S. Ohashi, M. Krones, and T.W. Mak. 1993. Mice deficient for the p55 tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to *L. monocytogenes* infection. *Cell.* 73:457–467.
22. Rothe, J., W. Lesslauer, H. Loetscher, Y. Lang, P. Koebel, F. Kontgen, A. Althage, R. Zinkernagel, M. Steinmetz, and H. Bluethmann. 1993. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by *Listeria monocytogenes*. *Nature (Lond.)* 364:798–802.
23. Heller, R.A., K. Song, N. Fan, and D.J. Chang. 1992. The p70 tumor necrosis factor receptor mediates cytokite activity. *Cell.* 70:47–56.
24. Heller, R.A., K. Song, and N. Fan. 1993. Cytotoxicity by tumor necrosis factor is mediated by both p55 and p70 receptors. *Cell.* 73:216.
25. Beutler, B.A., I.W. Millsar, and A. Cerami. 1985. Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. *J. Immunol.* 135:3972–3977.
26. Abe, Y., M. Gatanaga, Y. Osuka, S. Kimura, R.A. Burger, G.A. Granger, and T. Gatanaga. 1993. Role of 55- and 75-kDa tumor necrosis factor membrane receptors in the regulation of intercellular adhesion molecule-1 expression by HL-60 human promyelocytic leukemia cells in vitro. *J. Immunol.* 150:5070–5076.
27. Tartaglia, L.A., D.V. Goeddel, C. Reynolds, J.S. Figari, R.F. Weber, B.M. Fendly, and M.A. Palladino. 1993. Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor. *J. Immunol.* 151:4637–4641.
28. Sheehan, K.C.F., J. Calderon, and R.D. Schreiber. 1985. Generation and characterization of monoclonal antibodies specific for the human IFN-γ receptor. *J. Immunol.* 140:4231–4237.
29. Sheehan, K.C.F., N.H. Ruddle, and R.D. Schreiber. 1989. Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors. *J. Immunol.* 142:3884–3893.
30. Tartaglia, L.A., D. Pennica, and D.V. Goeddel. 1993. Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. *J. Biol. Chem.* 268:18542–18548.
31. Rogers, H.W., K.C.F. Sheehan, L.M. Brunt, S.K. Dower, E.R. Unanue, and R.D. Schreiber. 1992. Interleukin 1 participates in the development of anti-Listeria responses in normal and SCID mice. *Proc. Natl. Acad. Sci. USA.* 89:1011–1015.
32. Hockenbery, D., G. Nunez, C. Milliman, R.D. Schreiber, and S.J. Korsmeyer. 1990. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. *Nature (Lond.)* 348:334–336.
33. Hoggquist, K.A., M.A. Nett, K.C.F. Sheehan, K.D. Pendleton, R.D. Schreiber, and D.D. Chaplin. 1991. Generation of monoclonal antibodies to murine IL-1 beta and demonstration of IL-1 in vivo. *J. Immunol.* 146:1534–1540.
34. Celada, A., R. Allen, I. Esparza, P.W. Gray, and R.D. Schreiber. 1985. Demonstration and partial characterization of the interferon-gamma receptor on human mononuclear phagocytes. *J. Clin. Invest.* 76:2196–2205.
35. Hershey, G.K., and R.D. Schreiber. 1989. Biosynthetic analysis of the human interferon-gamma receptor. Identification of N-linked glycosylation intermediates. *J. Biol. Chem.* 264:11981–11988.
36. Laemmli, U.K. 1979. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature (Lond.)* 227:680–685.
37. Green, L.C., D.A. Wagner, J. Glogowski, P.L. Skipper, J. Wishnok, and S.R. Tannenbaum. 1982. Analysis of nitrate, nitrite, and [³¹⁵N]nitrate in biologic fluids. *Anal. Biochem.* 126:131–138.
38. Dighe, A.S., M.A. Farrar, and R.D. Schreiber. 1993. Inhibition of cellular responsiveness to interferon-γ (IFNγ) induced by overexpression of inactive forms of the IFNγ receptor. *J. Biol. Chem.* 268:10645–10653.
39. Galanos, C., M.A. Freudenberg, and W. Reutter. 1979. Galactosamine-induced sensitization to the lethal effects of endotoxin. *Proc. Natl. Acad. Sci. USA.* 76:5939–5943.
40. Buchmeier, N.A., and R.D. Schreiber. 1985. Requirement of endogenous interferon-gamma production for resolution of *Listeria monocytogenes* infection. *Proc. Natl. Acad. Sci. USA.* 82:7404–7408.
41. Gerasimidi, A, K.C.F. Sheehan, R.D. Schreiber, and P.E. Lacy. 1993. Tumor necrosis factor-α prevents rejection of islet xenografts (rat to mouse). *Diabetes.* 42:651–657.
42. Engelmann, H., H. Holtmann, C. Brakebusch, Y.S. Avni, I. Sarov, Y. Nophar, E. Hadas, O. Leitner, and D. Wallach. 1990. Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. *J. Biol. Chem.* 265:14497–14504.
43. Pennica, D., W.J. Kohl, B.M. Fendly, S.J. Shire, H.E. Raab, P.E. Bozhard, M. Lewis, and D.V. Goeddel. 1992. Characterization of a recombinant extracellular domain of the type 1 tumor necrosis factor receptor: evidence for tumor necrosis factor-α induced receptor aggregation. *Biochemistry.* 31:1134–1141.
44. Tartaglia, L.A., T.M. Ayres, G.H.W. Wong, and D.V. Goeddel. 1993. A novel domain within the 55 kd TNF receptor signals cell death. *Cell.* 74:845–853.
45. Erickson, S.L., F.J. de Sauvage, K. Kikly, K. Carver-Moore, S. Pitts-Meek, N. Gillett, K.C.F. Sheehan, R.D. Schreiber, D.V. Goeddel, and M.W. Moore. 1994. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2–deficient mice. *Nature (Lond.)* 372:560–563.
46. Bancroft, G.J., R.D. Schreiber, and E.R. Unanue. 1991. Natural immunity: a T-cell–independent pathway of macrophage activation defined in the scid mouse. *Immunol. Rev.* 124:5–24.
47. Piguet, P.F. 1993. TNF and the pathology of the skin. *Res. Immunol.* 144:320–326.
48. Rampart, M., W. De Smet, W. Fiers, and A.G. Herman. 1989. Inflammatory properties of recombinant tumor necrosis factor in rabbit skin in vivo. *J. Exp. Med.* 169:2227–2232.
49. Piguet, P.F., G.E. Grau, and P. Vassalli. 1990. Subcutaneous perfusion of tumor necrosis factor induces local proliferation of fibroblasts, capillaries, and epidermal cells, or massive tissue necrosis. *Am. J. Pathol.* 136:103–110.
50. Rothenstein, J.L., and H. Schreiber. 1988. Synergy between tumor necrosis factor and bacterial products causes hemorrhagic necrosis and lethal shock in normal mice. *Proc. Natl. Acad. Sci. USA.* 85:607–611.
51. Barbara, A.J., W.B. Smith, J.R. Gamble, X. Van Ostade, P. Vandenabeele, J. Tavernier, W. Fiers, M.A. Vadás, and A.F. Lopez. 1994. Dissociation of TNF-α cytoxic and proinflammatory activities by p55 receptor- and p75 receptor-selective TNF-α mutants. *EMBO (Eur. Mol. Biol. Organ.)* J. 13:843–850.